Abbvie (ABBV) Free Cash Flow (2016 - 2026)
Abbvie (ABBV) free cash flow from Sep 30, 2016 to Mar 31, 2026. The TTM Abbvie (ABBV) free cash flow is $20B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Free Cash Flow
Quarterly Free Cash Flow
Abbvie (ABBV) Free Cash Flow CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +29.87% |
| 3 Years TTM | -5.29% |
| 5 Years TTM | +2.35% |
| All Time TTM | +13.08% |
Annual Free Cash Flow change of Abbvie (ABBV)
| Year | Free Cash Flow | Change |
|---|---|---|
| 2026 | $3.56B | -80.00% |
| 2025 | $18B | -0.09% |
| 2024 | $18B | -19.17% |
| 2023 | $22B | -9.02% |
| 2022 | $24B | +10.27% |
| 2021 | $22B | +30.97% |
| 2020 | $17B | +31.46% |
| 2019 | $13B | -2101.88% |
| 2018 | -$638M | -109.08% |
| 2017 | $7.03B | +36.88% |
| 2016 | $5.13B | N/A |
Comparison Abbvie (ABBV) five years free cash flow CAGR with competitors
Abbvie (ABBV) five years free cash flow CAGR is 2.35%.
| Ticker | Name | five years Free Cash Flow CAGR | Upside |
|---|---|---|---|
| LLY | Lilly(Eli) & Company | 21.25% | +804.22% |
| AZN | Astrazeneca plc | 15.68% | +567.16% |
| NVS | Novartis AG | 9.71% | +313.14% |
| SNY | Sanofi | 8.08% | +243.98% |
| MRK | Merck & Co Inc | 5.49% | +133.59% |
| GILD | Gilead Sciences Inc | 3.30% | +40.32% |